Market Place
Sourcing Support
Trevena Reports Q3 2024 Results & Provides Business Update
07 Nov 2024 //
GLOBENEWSWIRE
Trevena Announces Receipt of Nasdaq Delisting Notification
04 Oct 2024 //
GLOBENEWSWIRE
Trevena Reports Second Quarter 2024 Results and Provides Business Update
08 Aug 2024 //
GLOBENEWSWIRE
Trevena Announces Reverse Stock Split
08 Aug 2024 //
GLOBENEWSWIRE
Trevena Announces $2M Non-Dilutive Financing And Liability Reduction
08 Jul 2024 //
GLOBENEWSWIRE
Trevena Reports Positive TRV045 Data In Pain And Epilepsy Preclinical Models
20 Jun 2024 //
GLOBENEWSWIRE
Trevena Reports First Quarter 2024 Results and Provides Business Update
15 May 2024 //
GLOBENEWSWIRE
Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
01 Apr 2024 //
GLOBENEWSWIRE
Trevena Announces the Closing of $4 Million Concurrent Private Placement
28 Dec 2023 //
GLOBENEWSWIRE
Trevena Announces $4 Million Concurrent Private Placement and Warrant Exercise
27 Dec 2023 //
GLOBENEWSWIRE
Trevena Awarded OLINVYK Agreement with Premier, Inc.
04 Dec 2023 //
GLOBENEWSWIRE
Trevena Announces TRV045 Presentation at 62nd Annual Meeting
04 Dec 2023 //
GLOBENEWSWIRE
Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK
30 Nov 2023 //
GLOBENEWSWIRE
Trevena Reports Third Quarter 2023 Results and Provides Business Update
14 Nov 2023 //
GLOBENEWSWIRE
Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023
09 Nov 2023 //
GLOBENEWSWIRE
Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data
16 Oct 2023 //
GLOBENEWSWIRE
Trevena Announces Completion of Analysis of OLINVYK Data from VOLITION Study
02 Oct 2023 //
GLOBENEWSWIRE
Trevena Announces TRV045 Data from Two Proof-of-Concept Studies Evaluating S1PR
06 Sep 2023 //
GLOBENEWSWIRE
Trevena Announces Receipt of $15 Million Non-Dilutive Tranche
06 Sep 2023 //
GLOBENEWSWIRE
Trevena Reports Second Quarter 2023 Results and Provides Business Update
14 Aug 2023 //
GLOBENEWSWIRE
Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors
20 Jul 2023 //
GLOBENEWSWIRE
Trevena Announces OLINVYK Data Highlighting Reduced Cost per Admission
26 Jun 2023 //
GLOBENEWSWIRE
Trevena Announces Receipt of Milestone Payment From Jiangsu Nhwa
31 May 2023 //
GLOBENEWSWIRE
Trevena Regains Compliance with Nasdaq Listing and Reaffirms Expected
30 May 2023 //
GLOBENEWSWIRE
Trevena Reports First Quarter 2023 Results and Provides Business Update
15 May 2023 //
GLOBENEWSWIRE
Trevena to Release First Quarter 2023 Financial Results on May 15, 2023
09 May 2023 //
GLOBENEWSWIRE
Trevena Announces Approval of OLINVYK in China
08 May 2023 //
GLOBENEWSWIRE
Trevena to Participate in Three Upcoming Conferences
03 May 2023 //
GLOBENEWSWIRE
Trevena Reports Fourth Quarter 2022 Results and Provides Business Update
30 Mar 2023 //
GLOBENEWSWIRE
Trevena Announces Initial Topline OLINVYK Data from ~200 Patient Outcomes Study
30 Mar 2023 //
GLOBENEWSWIRE
Trevena to Release Q4 and Full Year 2022 Financial Results on March 30, 2023
27 Mar 2023 //
GLOBENEWSWIRE
Trevena Initiates Targeted Proof-of-Concept Study to Evaluate TRV045
07 Mar 2023 //
GLOBENEWSWIRE
Trevena Announces Publication of OLINVYK Respiratory Study In ANESTHESIOLOGY
14 Feb 2023 //
GLOBENEWSWIRE
Trevena Enrolls 1stSubject in TRV045 Trial Evaluating S1PR Mechanism of Action
09 Jan 2023 //
GLOBENEWSWIRE
Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data
08 Dec 2022 //
GLOBENEWSWIRE
Trevena Regains Compliance with Nasdaq Listing Requirements
29 Nov 2022 //
GLOBENEWSWIRE
Trevena Announces Completion of Ph 1 Study for TRV045, Novel S1P Modulator
09 Nov 2022 //
GLOBENEWSWIRE
Trevena to Release Third Quarter 2022 Financial Results on November 9, 2022
07 Nov 2022 //
GLOBENEWSWIRE
Trevena Announces OLINVYK Presentation at ANESTHESIOLOGY Annual Meeting
24 Oct 2022 //
GLOBENEWSWIRE
Trevena Reports Second Quarter 2022 Results and Provides Business Update
11 Aug 2022 //
GLOBENEWSWIRE
Trevena to Release Second Quarter 2022 Financial Results on August 11, 2022
08 Aug 2022 //
GLOBENEWSWIRE
Trevena, Inc. Announces Closing of Registered Direct Offering of Preferred Stock
29 Jul 2022 //
GLOBENEWSWIRE
Small Pennsylvania biotech lays off a fourth of its staff
28 Jul 2022 //
ENDPTS
Trevena Announces Positive Topline OLINVYK Cognitive Function Data
28 Jul 2022 //
GLOBENEWSWIRE
Trevena Announces Publication of Expert Review on Clinical Profile of OLINVYK
14 Jun 2022 //
GLOBENEWSWIRE
Trevena to Participate at the JMP Securities Life Sciences Conference
10 Jun 2022 //
GLOBENEWSWIRE
Trevena to Present at the H.C. Wainwright Global Investment Conference
18 May 2022 //
GLOBENEWSWIRE
Trevena Reports First Quarter 2022 Results and Provides Business Update
11 May 2022 //
GLOBENEWSWIRE
Trevena to Release First Quarter 2022 Financial Results on May 11, 2022
09 May 2022 //
GLOBENEWSWIRE
Trevena COVID-19 treatment trial ceased due to early inferiority
26 Apr 2022 //
FIERCEBIOTECH
Trevena Receives First $15M Tranche + $40M ex-US Royalty-Based Financing
18 Apr 2022 //
GLOBENEWSWIRE
Trevena Reports Fourth Quarter and Full Year 2021 Results
31 Mar 2022 //
GLOBENEWSWIRE
Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing
31 Mar 2022 //
GLOBENEWSWIRE
Trevena to Release Fourth Quarter and Full Year 2021 Financial Results
30 Mar 2022 //
GLOBENEWSWIRE
Trevena Submits NDA in China for OLINVYK by Jiangsu Nhwa Pharmaceutical
27 Jan 2022 //
GLOBENEWSWIRE
Trevena Adds Seasoned Biopharma Commercial Executive to Senior Leadership Team
11 Nov 2021 //
GLOBENEWSWIRE
Trevena Announces Two OLINVYK® Presentations at ANESTHESIOLOGY® 2021
13 Oct 2021 //
GLOBENEWSWIRE
Trevena to Present at Oppenheimer 2021 Fall Healthcare Summit
17 Sep 2021 //
GLOBENEWSWIRE
Trevena Announces Two OLINVYK Abstracts Accepted at ANESTHESIOLOGY 2021
30 Aug 2021 //
GLOBENEWSWIRE
Trevena Announces Wake Forest Baptist Health Joining OLINVYK Study
25 Aug 2021 //
GLOBENEWSWIRE
